Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 141-150 of 656 for Cancer

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    Jacksonville, FL, Scottsdale/Phoenix, AZ

  2. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

    Rochester, MN

  3. Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors

    Rochester, MN

  4. Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

    Jacksonville, FL

  5. TheraSphere With and Without Durvalumab and Tremelimumab for HCC

    Jacksonville, FL

  6. Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

    Jacksonville, FL, Rochester, MN

  7. Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE)

    Rochester, MN

  8. Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  9. STOP-HER2: Stopping Trastuzumab in HER2+ MBC

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer